Objectives: The use of stem cell therapy for the repair of cartilage defects has shown promising results in in vitro and animal studies. However, only a small number of studies have been performed to evaluate the benefits in human subjects. The aim of this study is to systematically review studies that focus on the clinical application of stem cell therapy to treat cartilage defects in human subjects. Design: A literature search was performed, adhering to the PRISMA guidelines, to review any studies using such techniques in humans. Our initial search retrieved 105 articles listed on MEDLINE, EMBASE, Google Scholar, CINHal and SPortDiscus. From these studies, 11 studies meeting the eligibility criteria were selected and formed the basis of our systematic review. Results: There is limited evidence showing the benefit in humans. The study designs, follow-up methods and criteria reporting and evaluation vary greatly between the studies and are outlined in our systematic review. Conclusion: With an increasing body of evidence in non-human and in vitro studies, more human trials are required. More high level studies with extensive and robust validated reporting methods should be conducted to evaluate the true effect of such techniques in human cartilage defect repairs.
Introduction
Tissue is frequently damaged or lost in injury and disease of the musculoskeletal system. Advances in trauma and orthopaedic surgery have been highly successful in repairing, realigning, reconstructing and replacing damaged musculoskeletal structures. Tissue engineering is the science of generating replacement tissue for clinical use employing molecular and cellular techniques, combined with material engineering principles. This may involve the use of cells alone or with matrices. There has been an increasing interest in tissue engineering approaches such as stem cell applications in surgical practice to deal with damaged or lost tissue. Although there have been developments in the use of tissue engineering in almost all surgical disciplines, particularly significant advances are being made in orthopaedics, especially in cartilage repair 1 
.
Cartilage defects are often disabling and affect young, active patients. In many cases, normal function is not regained after treatment, and joint arthroplasty may not be a satisfactory option 2 . Techniques such as subchondral drilling, abrasion and microfracture result in the formation of fibrocartilage within the defect. Newer techniques such as autologous osteochondral transplantation and autologous chondrocyte implantation (ACI) have been developed 3 .
The use of stem cell therapy is an exciting alternative strategy that aims to form hyaline cartilage within the defect. This newly formed hyaline like cartilage would integrate with the surrounding normal cartilage and be mechanically functional 4 .
Numerous in vivo animal studies show the potential benefits of using stem cells to treat musculoskeletal diseases. However, given the complexity of the treatment and the potential ethical and economic considerations, only a few have been translated into human clinical studies 2 . The aim of this article is to review studies that focus on the clinical application of stem cell therapy to treat cartilage defects in skeletally mature human subjects.
Methods
This review was undertaken in accordance with the PRISMA guidelines. All articles not in English were excluded. The study selection process involved screening the study titles to check their relevance to the subject. The abstracts and included articles were subsequently reviewed by two of the authors (PP and WSK) independently to check the primary goal and outcome measures of each included study. Eligible studies had to report outcomes regarding function or pain scores, and have a reasonable follow-up period. All journals were considered, and all relevant articles were retrieved. A hand search for studies meeting the inclusion criteria was performed on the reference lists of included studies and relevant review articles. Articles that described surgical techniques without patient follow-up, commentaries or review articles were also excluded.
Results
The results retrieved 105 articles listed on MEDLINE, EMBASE, Google Scholar, CINHal and SPortDiscus. The selection process is shown in a flow diagram in Fig. 1 . One article was a review of all of the patients treated by the same research team and was thus excluded 5 . Following this process, the resulting 11 articles formed the basis of our review 6e16 . The details of the included studies are summarised in Tables I and II. Of the included studies, there was no randomised controlled trial. The other studies were prospective case series, cohort and case control studies, and case reports. There were three studies that included patients not treated with Mesenchymal Stem Cells (MSCs); a cohort study compared ACI with MSC implantation 8 , a case control study evaluated patients undergoing a high tibial osteotomy alone or in combination with MSC implantation 12 , and lastly a prospective cohort study comparing open ACI procedures, arthroscopic ACI procedures and arthroscopic implantation of bone marrow derived cells 14 . Although the data for all study groups is presented in Tables I and II , only the MSC group was included in further analyses. Two studies by the same research group with 73 patients used cartilage defects arising from the talar dome in the ankle joint 13, 14 . All of these lesions were defined as grade II lesions. The remaining nine studies with 96 patients investigated defects in the knee joint. These lesions were defined as grade III or grade IV in 82 patients. Two studies 9,12 with 14 patients did not specify the grade of the lesion. Of the knee lesions in the 96 patients, 59 involved the femoral condyles, 23 involved the patella, 10 involved the trochlea, 13 were multiple and two were not specified. Out of the 59 femoral condylar lesions 35 were located at the medial condyle, 10 at the lateral condyle and two at both condyles. The location of 12 femoral condylar lesions was not specified. Of the 23 patellar lesions, three were multiple. The number of patients undergoing additional procedures in the knee joint was 52. Twenty-five patients underwent a high tibial osteotomy, seven patients underwent partial meniscectomy, 10 underwent anterior cruciate ligament (ACL) reconstruction, seven underwent patella realignment surgery, one patient had a lateral release, one patient had a meniscal repair, and one had an osteophyte removed. A calcaneal osteotomy was the only one additional ankle procedure 14 in the 73 ankle patients.
The two studies involving the ankle joint 13, 14 and one study involving the knees of 20 patients 14 isolated bone marrow derived
MSCs from the posterior iliac crest, whereas all other studies used the anterior iliac crest. The implantation timing and methods also varied. The three studies using the posterior iliac crest harvest implanted the bone marrow derived cells immediately whereas the other studies culture expanded the MSCs in vitro and performed a second-stage implantation procedure at a later date. The MSCs were expanded in culture for 3e4 weeks in most cases; for seven patients involved in two studies 6,7 the duration is not specified.
Collagen was the most commonly used scaffold and was used with a periosteal flap in 54 patients and with platelet rich fibrin in 23 patients. Hyaluronic acid was used with platelet rich fibrin in 45 patients. In one study 14 involving 25 patients either a collagen or hyaluronic acid scaffold was used, but not specified. A platelet rich fibrin scaffold with a periosteal flap was used for five patients. 7 One study involving two patients did not specify the scaffold used 9 .
In terms of outcome measurements and post-implantation evaluation of cartilage regeneration, there were marked differences. Most studies utilised one or more validated objective and subjective scoring systems such as the American Orthopaedic Foot and Ankle Society (AOFAS) score, Lysholm score, Knee injury and Osteoarthritis Outcome Score (KOOS), International Knee Documentation Committee (IKDC) score and the Revised Hospital for Special Surgery Knee (RHSSK) score. Only two studies used a validated scoring system to assess the appearance of the actual transplanted cartilage; Haleem et al. 6 had only an arthroscopy and nine patients 7 had both an MRI and arthroscopy. In all of these patients there was radiological and/or arthroscopic evidence of full integration of the lesion. A further 34 patients were investigated with an arthroscopy and a biopsy of the implantation site, 15 of whom also had an MRI. Of these, 31 8,13e16 were histologically reported as 'hyaline' or 'hyalinelike', while the remaining three 9,10 were reported as 'fibrocartilage'.
The quality of the included studies was assessed using the Coleman Methodology Score (CMS), that assesses methodology using 10 criteria, giving a total score between 0 and 100 as shown in Table III . A score of 100 indicates that the study largely avoids chance, various biases and confounding factors. , mean depth 4.0 AE 0.9 mm). All patients underwent immediate implantation of bone marrow derived cells from the posterior iliac crest under general anaesthetic (GA) using either a collagen or hyaluronic acid scaffold. All patients were evaluated pre and post-operatively with AOFAS scores as well as MRI scans. In addition, five patients also had a biopsy at 12 months time showing hyaline cartilage like tissue.
Discussion
The 'holy grail' in the management of osteoarthritis and cartilage loss, especially in the initial stages is to repair the affected area and thus halt the progression of the damage. Arthroplasty for severe disease or for older individuals is a well recognised and successful treatment option.
ACI procedures have shown promising results in the short to medium term 17, 18 . However a recent meta-analysis of several leading databases showed that although the clinical outcomes Cells used in tissue engineering could be autologous, allogeneic or xenogeneic. The cells could be stem cells or cells further down the differentiation pathway. Stem cells possess self-renewal capacity, and exhibit long-term viability and multilineage differentiation potential. Ethical, political and religious issues surround the use of embryonic stem cells. In contrast, the use of autologous adult stem cells is generally well accepted. Stem cells have been identified in a number of adult tissues, albeit in small numbers. In addition to bone marrow, MSCs have been identified in other tissues including adipose tissue and fat pad from which MSCs are generally isolated and subsequently expanded in culture 1 . These cells are characterised or defined using a set of cell surface markers and can then be differentiated along a given differentiation pathway, e.g., osteoblast or chondrocyte, using predefined culture conditions before being used for clinical applications 20, 21 . MSCs are less tumorigenic than their embryonic counterparts 22 , and provide an autologous source of cells eliminating concerns regarding rejection and disease transmission. There is also evidence to suggest that MSCs have immunosuppressive potential as coculture with MSCs inhibits T-cell lymphocyte proliferation 23 , and
MSCs have also been shown to be negative for major histocompatibility complex (MHC) class II antigens and the costimulatory molecules B7-1 and B7-2 24, 25 . Animal and in vitro studies have shown that there is a place for the use of stem cells in the management of musculoskeletal conditions 26 . Based on the success reported on such studies, there is clear evidence that over the last few years the appeal to translate this potential benefit to human subjects is growing. As evident from the CMS, there was a wide difference in methodology scores. The studies included in this review are not homogeneous and vary between each other in both study design and outcome measurements. Seven of these studies are case reports or series, one is a case control, one is a cohort study, and only two are randomised controlled trials.
With a total of 81 patients, Giannini et al. 14 12 allocated two groups of 12 patients to either a high tibial osteotomy or a high tibial osteotomy with the application of MSCs. The authors did not give objective details of post-operative recovery or rehabilitation regimens. They did however comment that histological, visual (via arthroscopy) and patient reported outcomes (the scoring system used was not commented on) were better in the group treated with the addition of MSCs. Despite the discrepancy in methodology and outcome measurements, the summary table provided reveals several similarities. Outcomes in all studies were highly satisfactory and promising. Harvesting of the stem cells was undertaken in a similar fashion from the iliac crest with no reported complications.
When formal outcome measures were administered, there were statistically significant improvements. Kasemkijwattan et al. reported significant improvements in their case series with the Knee injury and Osteoarthritis Outcome Score (KOOS) and the IKDC score 6 . This was further supported by arthroscopy confirming full integration of what appeared to be a cartilage-like lesion within the treated defect. No biopsy was undertaken. Haleem et al. 7 confirmed improvements using Lysholm and RHSSK scores in a series of five patients at six at 12 months. Additionally, two of five patients consented to arthroscopy, and both had nearly normal International Cartilage Repair Society (ICRS) arthroscopic scores at 12 months. Nejadnik et al. 8 reported improvement in patient SF 36
Questionnaire results pre-and post-treatment, but no significant improvements in IKDC, Lysholm and Tegner Activity scores. Buda et al. 15 undertook a detailed prospective follow-up for their case series of 20 osteochondral defects. They reported significant improvements in IKDC and KOOS scores at 2 years post-application of MSC patches to the defects. This is one of only two studies included in this review to assess the results using the MOCART scoring system. At 2 years post-procedure, they noted that 14 of 20 defects had been repaired, and 16 lesions had undergone complete integration with the surrounding cartilage. However, only six lesions were homogenous in structure and presented intact with subchondral lamina and bone. Of the 20 samples, two had an arthroscopic biopsy and histological examination at 1 year, which confirmed type II cartilage formation. Battaglia et al. 27 undertook a qualitative MRI study to evaluate the efficacy of bone marrow derived cell transplantation to repair osteochondral lesions. They aimed to investigate the validity of MRI T2-mapping sequence in characterising the reparative tissue obtained and its ability to correlate with clinical results. They used a cohort group of 20 patients, recruited from a study included in this paper 13 , who underwent treatment for talar dome osetochondral lesions. They were compared to a matched group of 20 healthy volunteers. MRI results evaluated by MOCART scores showed that the defect filling was complete in nine patients (45%), hypertrophic in a further nine patients (45%), and incomplete with less than 50% defect repair in two patients (10%). Integration to border zone was complete in 13 patients (65%), the surface of repair tissue was intact in eight patients (40%), and the reparative tissue was isointense in 14 patients (70%). A regenerated tissue with a mean T2 map value of 35e45 ms was considered compatible with the normal hyaline cartilage and was found in all the cases, covering a mean percentage of 78% of the repaired lesion area. A tissue with T2 map value <35 ms was considered expression of a fibrocartilaginous regenerative tissue. It was found in limited foci (<10% of the repaired site) in 13 patients (65%), and in up to 50% of the repaired lesion area in one patient (5%). MOCART scores were then compared with clinical outcome scores (AOFAS). Patients with a repaired tissue's signal that was isointense with respect to normal hyaline cartilage (14 cases) had a median AOFAS score of 100, while patients with a comparative moderate signal hyperintensity with respect to normal hyaline cartilage (six cases) obtained a mean score of 89. Comparing the T2 mapping with the clinical scores, they found a statistically significant (P ¼ 0.05) relationship between the clinical score and the percentage of the lesion area repaired by tissue with a signal compatible with hyaline cartilage.
Comparative studies such as those by Giannini et al. 13 and
Nejadnik et al. 8 showed significantly improved outcomes for patients who either underwent ACI or stem cell techniques, highlighting that there may be a role for both of these treatment regimens. Although three of the included studies had two or fewer subjects, they all reported good patient outcome scores and add to the growing body of evidence supporting the use of stem cells in the treatment of osteochondral defects.
Limitations of current evidence
Several limitations are evident in the studies included in the present review. Several centres and authors seem to have been involved in a number of these investigations, therefore potentially introducing bias into the subject. There were also different ways of assessing the results, which is reflected in the CMS for each trial (Table III) . The benefit of using scaffolds is still unclear. There are also differences in the methods of reporting outcome measures: some trials used recognised functional scoring systems, supported by imaging and histological scores.
Most of the studies involve additional procedures other than those directly related to the repair of cartilage defects, such as ACL reconstructions, meniscectomies and cheilectomies. Therefore it is possible that the functional outcome results may be partially or even completely attributed to these secondary procedures.
Post-operative rehabilitation regimens, when reported, vary between individual studies. It appears that they generally involve a period of immobilisation following the procedures. However, there is no agreed consensus on details or duration of the weight bearing status.
There is the need for a robust prospective randomised control clinical trial that is adequately powered, with patients followed up for initially the medium-term and then the longer-term. It is also important that the study when published has adequate details on the surgical technique and clinical post-operative management allowing others to replicate the process satisfactorily. There is an ever-increasing number of outcome measures available and it would be important for future studies to use validated, reliable and responsive outcome measures that are not subject to bias. These will need to be supplemented with further evaluations including MRI scans, and arthroscopic and histological analyses in at least a subgroup of patients.
Furthermore, other types of stem cells such as synovial and adipocyte stem cells may also have a role to play in stem cell therapies for cartilaginous joint defects, however these are beyond the scope of this paper.
Conclusion
The success of stem cell treatment for osteochondral defects in animals in vivo is well established. Currently there is a small body of evidence showing that, if this technique is transferred into human patients, the benefits also appear to be translated. However, any benefit to human subjects still requires extensive evaluation. Tissue engineering techniques in humans are still very much in its infancy. Higher level of evidence studies are needed, with robust methodology and outcome measures so that any perceived benefit can be clearly evaluated and pursued further.
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